Switch theme
Sign up to access all valuation multiples
Amphastar Pharmaceuticals Inc is a bio-pharmaceutical company focusing on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin active pharmaceutical ingredient, or insulin API products. The company's finished products are used in hospital or urgent care clinical settings and are contracted and distributed through group purchasing organizations and drug wholesalers. The company has one reportable segment pharmaceutical products. Geographically the business presence of the firm is seen in the United States, China and France of which the U.S. accounts for the majority of the revenue.
2004
2.0K+
LTM Revenue $732M
LTM EBITDA $284M
$1.6B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Amphastar Pharma has a last 12-month revenue of $732M and a last 12-month EBITDA of $284M.
In the most recent fiscal year, Amphastar Pharma achieved revenue of $732M and an EBITDA of $277M.
Amphastar Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Amphastar Pharma valuation multiples based on analyst estimates| FY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
|---|---|---|---|---|---|
| Revenue | $644M | $732M | XXX | XXX | XXX |
| Gross Profit | $249M | $351M | XXX | XXX | XXX |
| Gross Margin | 39% | 48% | XXX | XXX | XXX |
| EBITDA | $240M | $277M | XXX | XXX | XXX |
| EBITDA Margin | 37% | 38% | XXX | XXX | XXX |
| Net Profit | $91.4M | $138M | XXX | XXX | XXX |
| Net Margin | 14% | 19% | XXX | XXX | XXX |
| Net Debt | n/a | $446M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Amphastar Pharma's stock price is $24.
Amphastar Pharma has current market cap of $1.2B, and EV of $1.6B.
See Amphastar Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.6B | $1.2B | XXX | XXX | XXX | XXX | $3.65 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Amphastar Pharma has market cap of $1.2B and EV of $1.6B.
Amphastar Pharma's trades at 2.2x LTM EV/Revenue multiple, and 5.6x LTM EBITDA.
Analysts estimate Amphastar Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Amphastar Pharma and 10K+ public comps| FY 2024 | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|
| EV | $1.6B | XXX | XXX | XXX |
| EV/Revenue | 2.2x | XXX | XXX | XXX |
| EV/EBITDA | 5.7x | XXX | XXX | XXX |
| P/E | 7.3x | XXX | XXX | XXX |
| P/E/Growth | 0.7x | XXX | XXX | XXX |
| EV/FCF | 9.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpAmphastar Pharma's NTM/LTM revenue growth is 2%
Amphastar Pharma's revenue per employee for the last fiscal year averaged $0.4M, while opex per employee averaged $0.1M for the same period.
Over next 12 months, Amphastar Pharma's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Amphastar Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Amphastar Pharma and other 10K+ public comps| FY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
|---|---|---|---|---|---|
| Revenue Growth | 14% | XXX | XXX | XXX | XXX |
| EBITDA Margin | 38% | XXX | XXX | XXX | XXX |
| EBITDA Growth | 15% | XXX | XXX | XXX | XXX |
| Rule of 40 (SaaS-only) | 40% | XXX | XXX | XXX | XXX |
| Revenue per Employee | $0.4M | XXX | XXX | XXX | XXX |
| Opex per Employee | $0.1M | XXX | XXX | XXX | XXX |
| S&M Expenses to Revenue | 5% | XXX | XXX | XXX | XXX |
| G&A Expenses to Revenue | 8% | XXX | XXX | XXX | XXX |
| R&D Expenses to Revenue | 10% | XXX | XXX | XXX | XXX |
| Opex to Revenue | 23% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Amphastar Pharma acquired XXX companies to date.
Last acquisition by Amphastar Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . Amphastar Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign Up| When was Amphastar Pharma founded? | Amphastar Pharma was founded in 2004. |
| Where is Amphastar Pharma headquartered? | Amphastar Pharma is headquartered in United States of America. |
| How many employees does Amphastar Pharma have? | As of today, Amphastar Pharma has 2.0K+ employees. |
| Who is the CEO of Amphastar Pharma? | Amphastar Pharma's CEO is Dr. Jack Yongfeng Zhang. |
| Is Amphastar Pharma publicy listed? | Yes, Amphastar Pharma is a public company listed on NAS. |
| What is the stock symbol of Amphastar Pharma? | Amphastar Pharma trades under AMPH ticker. |
| When did Amphastar Pharma go public? | Amphastar Pharma went public in 2014. |
| Who are competitors of Amphastar Pharma? | Similar companies to Amphastar Pharma include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Amphastar Pharma? | Amphastar Pharma's current market cap is $1.2B |
| What is the current revenue of Amphastar Pharma? | Amphastar Pharma's last 12-month revenue is $732M. |
| What is the current EBITDA of Amphastar Pharma? | Amphastar Pharma's last 12-month EBITDA is $284M. |
| What is the current EV/Revenue multiple of Amphastar Pharma? | Current revenue multiple of Amphastar Pharma is 2.2x. |
| What is the current EV/EBITDA multiple of Amphastar Pharma? | Current EBITDA multiple of Amphastar Pharma is 5.6x. |
| What is the current revenue growth of Amphastar Pharma? | Amphastar Pharma revenue growth between 2023 and 2024 was 14%. |
| Is Amphastar Pharma profitable? | Yes, Amphastar Pharma is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
